查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087631

結核病診斷市場：全球市場按產品類型、技術、檢測類型、最終用戶和應用分類的預測，2026-2032年

Tuberculosis Diagnostics Market by Product, Technology, Test Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，結核病診斷市場將成長至 38.8 億美元，複合年成長率為 6.77%。

主要市場統計數據
基準年 2025 24.5億美元
預計年份：2026年 25.9億美元
預測年份 2032 38.8億美元
複合年成長率 (%) 6.77%

結核病診斷在全球結核病控制中發揮核心作用，因為早期準確檢測決定了患者能否盡快獲得有效治療，以及能否盡快切斷感染鏈。根據世界衛生組織（世衛組織）估計，到2023年，全球將有1,080萬人罹患結核病，125萬人將死於該疾病。這凸顯了無論結核病發生率高低，都需要進行大規模結核病檢測。

該市場涵蓋痰液塗片顯微鏡檢查、分枝桿菌培養、分子診斷、線性探針檢測、藥物敏感性試驗、 干擾素釋放試驗、針對特定人群的尿脂阿拉伯甘露聚醣（LAA）側向層析檢測以及基於電腦輔助檢測（CAD）的數位胸部X光片。市場需求主要受國家結核病根除計畫、抗菌藥物抗藥性監測、分散式分子檢測以及彌合抗藥性結核病、兒童結核病、肺外結核病和HIV相關結核病診斷差異的努力所驅動。

結核病診斷領域的變革性變化

結核病診斷格局正從以顯微鏡檢查為中心的集中式工作流程轉變為更快、更分散、數位互聯的檢測模式。世界衛生組織建議的核酸增幅檢查等快速診斷方法，因其能比培養法更快地檢測出結核分枝桿菌複合群和關鍵的利福平抗藥性標記物，正日益被優先用作初始檢測方法。

人工智慧對結核病診斷的累積影響

人工智慧正透過篩檢處理能力、提高分流準確性、最佳化工作流程優先順序和增強監測訊息，對整個結核病診斷流程產生累積影響。世界衛生組織指南建議使用電腦輔助檢測（CAD）軟體輔助解讀15歲及以上人群的胸部X光相片，以進行結核病篩檢和分診，從而擴大放射診斷能力，即使在訓練有素的放射科醫生有限的地區也能發揮作用。

結核病診斷的主要區域趨勢

亞太地區仍是全球結核病診斷中心，這主要得益於結核病負擔沉重且擁有大規模公共檢測網路的國家。印度、中國、印尼、菲律賓和越南持續增加對分子診斷平台、數位胸部X光片、檢體運輸系統和抗藥性檢測的投資，並輔以符合世衛組織建議的國家結核病控制策略。北美地區的特點是結核病發病率低、檢查室品管系統健全、在移民和社區生活環境中篩檢、有效管理潛伏性結核感染，以及採用先進的分子診斷和免疫學檢測技術。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

東南亞國協正透過公共部門採購快速分子診斷系統、擴大社區篩檢、捐助者支持的檢查室現代化改造，加強結核病診斷能力。該地區龐大的人口基數、跨境流動以及對抗藥性的持續擔憂，使得各國迫切需要連網、價格合理且易於取得的檢測平台，以支持在人口稠密的都市區、島嶼社區和偏遠地區開展病例發現工作。

主要結核病診斷市場的國家/地區特定洞察

美國和加拿大正著力進行針對性檢測、潛伏性結核感染管理、加強公共衛生檢查室能力以及快速檢測抗藥性，特別關注外來人口和有明確暴露風險的人口。墨西哥和巴西正在擴大分子檢測的覆蓋範圍，同時解決區域差異問題，應對都市區的高風險族群，並確保篩檢、確診和治療啟動的連續性。在歐洲，英國、德國、法國、義大利和西班牙則致力於控制低發病率、篩檢移民、追蹤密切接觸者以及進行先進的實驗室診斷，而俄羅斯仍然是抗藥性結核病檢測、培養能力和監測的重要市場。

為行業領導者提供的實用建議

產業領導者應優先考慮世界衛生組織建議的診斷類別、本地臨床檢驗以及符合結核病高負擔地區實際操作情況的產品設計。成功的策略包括分散式分子檢測、完善的維護模式、不間斷的試劑盒和試劑供應、適用於服務不足環境的營運方案、注重生物安全的檢體處理以及與電子結核病登記系統的整合。

調查方法

本執行摘要基於二手研究，參考了權威的公共衛生資料，包括世界衛生組織結核病指南、全球結核病監測數據、國家結核病控制規劃優先事項、監管趨勢、同行評審的診斷性能證據以及有關分子檢測、放射學篩檢、人工智慧輔助篩檢和藥物敏感性檢測的公開資訊來源。

結論

結核病診斷正朝著更快、更分散、人工智慧驅動的時代邁進。分子檢測、數位X光成像、人工智慧篩檢、抗藥性檢測和協同監測的結合，正在重塑醫療系統檢測、確診結核病並啟動有效治療的方式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 結核病診斷市場：依產品分類

  • 消耗品
    • 成套工具
    • 試劑
  • 裝置

第8章 結核病診斷市場：依技術分類

  • 分子
    • 基因分型
    • 核酸增幅檢查
  • 非分子方法
    • 診斷影像
    • 免疫測定

第9章 結核病診斷市場：依檢測類型分類

  • 檢測測試
    • 驗血
    • 培養試驗
    • 分子檢測
    • 皮膚反應測試
    • 塗片顯微鏡檢查
  • 藥物敏感性試驗
    • 分子DST
    • 表現型藥物敏感性試驗

第10章 結核病診斷市場：依最終用戶分類

  • 診所
  • 醫院
  • 參考實驗室

第11章 結核病診斷市場：依應用分類

  • 活動性肺結核
    • 肺外結核病
    • 肺結核
  • 潛伏性結核病

第12章 結核病診斷市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 結核病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 結核病診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis Group NV
  • bioMerieux SA
  • Bruker Corporation.
  • Creative Diagnostics
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Hologic, Inc.
  • Kindstar Globalgene Technology, Inc.
  • Lionex GmbH
  • Molbio Diagnostics Limited
  • QIAGEN NV
  • Revvity, Inc.
  • SD Biosensor, Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Zhejiang Di'an Diagnostics Technology Co., Ltd.
Product Code: MRR-03252A5F9274

The Tuberculosis Diagnostics Market is projected to grow by USD 3.88 billion at a CAGR of 6.77% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.45 billion
Estimated Year [2026] USD 2.59 billion
Forecast Year [2032] USD 3.88 billion
CAGR (%) 6.77%

Tuberculosis diagnostics are central to global TB control because early, accurate detection determines how quickly patients receive effective therapy and how rapidly transmission chains are interrupted. According to the World Health Organization, an estimated 10.8 million people developed TB in 2023, while 1.25 million people died from the disease, underscoring the need for scalable tuberculosis testing across high-burden and low-incidence settings.

The market spans sputum smear microscopy, mycobacterial culture, molecular diagnostics, line probe assays, drug-susceptibility testing, interferon-gamma release assays, lateral flow urine lipoarabinomannan testing for eligible populations, and digital chest X-ray supported by computer-aided detection. Demand is being shaped by national TB elimination programs, antimicrobial resistance surveillance, decentralized molecular testing, and the push to close diagnostic gaps for drug-resistant tuberculosis and pediatric, extrapulmonary, and HIV-associated TB.

Transformative Shifts in the Tuberculosis Diagnostics Landscape

The tuberculosis diagnostics landscape is shifting from centralized, microscopy-led workflows toward faster, more decentralized, and digitally connected testing models. WHO-recommended rapid diagnostics, including nucleic acid amplification tests, are increasingly prioritized as initial tests because they can detect Mycobacterium tuberculosis complex and key rifampicin-resistance markers far faster than culture-based methods.

At the same time, health systems are expanding case-finding beyond symptomatic clinic presentation. Digital radiography, targeted screening in high-risk populations, integrated TB-HIV services, and drug-resistance testing are changing procurement priorities. These shifts favor diagnostics that combine accuracy, operational simplicity, connectivity, and suitability for district laboratories, mobile screening units, prisons, mines, refugee settings, and primary care facilities.

Cumulative Impact of Artificial Intelligence on TB Diagnostics

Artificial intelligence is having a cumulative impact across the TB diagnostic pathway by improving screening throughput, triage accuracy, workflow prioritization, and surveillance intelligence. WHO guidance supports computer-aided detection software for interpreting chest radiographs in TB screening and triage among people aged 15 years and older, enabling programs to extend radiology capacity where trained readers are limited.

AI does not replace confirmatory microbiological testing, culture, or drug-susceptibility testing, but it strengthens the front end of the diagnostic cascade. When paired with digital X-ray, molecular confirmation, laboratory information systems, and geospatial analytics, AI can reduce missed cases, prioritize high-risk individuals for nucleic acid amplification testing, support quality assurance, and improve program monitoring. The strongest adoption opportunities are in settings where algorithms are locally validated, bias is monitored, data governance is clear, and results are linked to rapid treatment initiation.

Key Regional Insights for Tuberculosis Diagnostics

Asia-Pacific remains the center of global TB diagnostic demand, led by high-burden countries and large public-sector testing networks. India, China, Indonesia, the Philippines, and Vietnam continue to drive investment in molecular platforms, digital chest X-ray, sample transport systems, and drug-resistance detection, supported by national TB strategies aligned with WHO recommendations. North America is characterized by low-incidence TB control, strong laboratory quality systems, immigration and congregate-setting screening, latent TB infection management, and adoption of advanced molecular and immunological testing.

Latin America is expanding access to rapid molecular diagnostics while addressing uneven laboratory coverage across urban, rural, and border communities, with Brazil and Mexico playing important roles in public-sector TB testing scale-up. Europe combines low-incidence elimination strategies in Western Europe with heightened attention to migration-linked screening, cross-border surveillance, and drug-resistant TB risks in parts of Eastern Europe. The Middle East is shaped by migrant-worker screening, hospital-based diagnostics, and GCC investments in public health infrastructure. Africa remains a critical region because high TB-HIV burden, delayed diagnosis, and limited laboratory access create substantial demand for decentralized nucleic acid amplification testing, urine lipoarabinomannan testing for eligible people with HIV, mobile radiography, and connected surveillance systems.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries are strengthening TB diagnostic capacity through public-sector procurement of rapid molecular systems, expanded community screening, and donor-supported laboratory modernization. The region's large population base, cross-border mobility, and persistent drug-resistance concerns create demand for connected, affordable, and field-ready testing platforms that can support case detection across dense urban areas, islands, and remote communities.

The GCC emphasizes pre-employment and residency-linked screening, high-quality hospital diagnostics, and digital health integration as part of broader infectious disease control. The European Union prioritizes TB elimination, quality-assured laboratory networks, and coordinated surveillance, while BRICS economies are pivotal because Brazil, Russia, India, China, and South Africa combine large testing volumes with domestic manufacturing ambitions, high-burden settings, and strong policy influence. G7 markets focus on innovation, regulatory quality, latent TB management, and low-incidence TB control, whereas NATO countries increasingly view infectious disease detection, laboratory readiness, and resilient supply chains as part of broader health security planning.

Key Country Insights for Major Tuberculosis Diagnostics Markets

The United States and Canada focus on targeted testing, latent TB infection management, public health laboratory capacity, and rapid detection of drug resistance, particularly among foreign-born populations and people with defined exposure risks. Mexico and Brazil are expanding access to molecular testing while addressing regional disparities, high-risk urban populations, and continuity between screening, confirmation, and treatment initiation. In Europe, the United Kingdom, Germany, France, Italy, and Spain emphasize low-incidence control, migrant screening, contact investigation, and advanced laboratory diagnostics, while Russia remains a significant market for drug-resistant TB detection, culture capacity, and surveillance.

China and India are the most influential country markets because of scale, national TB programs, domestic diagnostic manufacturing, and large public-sector procurement, with both countries investing in faster detection and broader drug-resistance testing. Japan, Australia, and South Korea maintain advanced diagnostic infrastructure, strong regulatory systems, and emphasis on screening high-risk populations, older adults, contacts, and foreign-born communities. Across these countries, the competitive advantage increasingly favors solutions that combine WHO-aligned performance, affordability, connectivity, reliable service support, biosafety compliance, and compatibility with national reporting systems.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize WHO-recommended diagnostic categories, local clinical validation, and product designs that meet the operational realities of high-burden settings. Successful strategies include decentralized molecular testing, robust maintenance models, uninterrupted cartridge and reagent availability, low-infrastructure operating options, biosafety-aware sample handling, and integration with electronic TB registers.

Organizations should also invest in partnerships with national TB programs, global health funders, private laboratory chains, community screening initiatives, and radiology networks. AI-enabled screening tools should be deployed with transparent performance evidence, bias monitoring, cybersecurity safeguards, local validation, and clear referral pathways for confirmatory testing. Manufacturers that align pricing, training, logistics, connectivity, and quality assurance with public health goals will be better positioned to win long-term procurement contracts and improve patient outcomes.

Research Methodology

This executive summary is based on secondary research from authoritative public health sources, including WHO tuberculosis guidance, global TB surveillance data, national TB program priorities, regulatory trends, peer-reviewed evidence on diagnostic performance, and publicly available information on molecular testing, radiography, AI-enabled screening, and drug-susceptibility testing.

The methodology emphasizes triangulation across epidemiology, technology adoption, policy direction, procurement behavior, laboratory infrastructure, and regional disease burden. Insights were evaluated for relevance to tuberculosis diagnostics, including active TB detection, drug-resistant TB identification, latent TB testing, screening, triage, laboratory workflow, and digital reporting. No unsupported market-size, market-share, or forecasting claims are used; conclusions are grounded in verified disease burden, guideline evolution, and observable diagnostic deployment trends.

Conclusion

Tuberculosis diagnostics are moving into a more rapid, decentralized, and intelligence-enabled era. The combination of molecular testing, digital radiography, AI-supported screening, drug-resistance detection, and connected surveillance is reshaping how health systems find TB, confirm infection, and initiate effective treatment.

The strongest opportunities will emerge where diagnostic technologies are affordable, quality assured, locally validated, and embedded in patient-centered care pathways. As countries work toward TB elimination targets, industry leaders that support equitable access, reliable supply, and measurable public health impact will define the next phase of progress in the global tuberculosis diagnostics market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Tuberculosis Diagnostics Market, by Product

  • 7.1. Consumables
    • 7.1.1. Kits
    • 7.1.2. Reagents
  • 7.2. Instruments

8. Tuberculosis Diagnostics Market, by Technology

  • 8.1. Molecular
    • 8.1.1. Genotypic Assays
    • 8.1.2. Nucleic Acid Amplification Tests
  • 8.2. Nonmolecular
    • 8.2.1. Imaging
    • 8.2.2. Immunological Assays

9. Tuberculosis Diagnostics Market, by Test Type

  • 9.1. Detection Test
    • 9.1.1. Blood Tests
    • 9.1.2. Culture-Based Tests
    • 9.1.3. Molecular Tests
    • 9.1.4. Skin Tests
    • 9.1.5. Smear Microscopy
  • 9.2. Drug Susceptibility Testing
    • 9.2.1. Molecular Dst
    • 9.2.2. Phenotypic Dst

10. Tuberculosis Diagnostics Market, by End User

  • 10.1. Clinics
  • 10.2. Hospitals
  • 10.3. Reference Laboratories

11. Tuberculosis Diagnostics Market, by Application

  • 11.1. Active Tb
    • 11.1.1. Extrapulmonary Tb
    • 11.1.2. Pulmonary Tb
  • 11.2. Latent Tb

12. Tuberculosis Diagnostics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Tuberculosis Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Tuberculosis Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Becton, Dickinson and Company
  • 16.3. Bio-Rad Laboratories, Inc.
  • 16.4. Biocartis Group NV
  • 16.5. bioMerieux SA
  • 16.6. Bruker Corporation.
  • 16.7. Creative Diagnostics
  • 16.8. Danaher Corporation
  • 16.9. DiaSorin S.p.A.
  • 16.10. F. Hoffmann-La Roche Ltd.
  • 16.11. Fujifilm Holdings Corporation
  • 16.12. Hologic, Inc.
  • 16.13. Kindstar Globalgene Technology, Inc.
  • 16.14. Lionex GmbH
  • 16.15. Molbio Diagnostics Limited
  • 16.16. QIAGEN N.V.
  • 16.17. Revvity, Inc.
  • 16.18. SD Biosensor, Inc.
  • 16.19. Seegene Inc.
  • 16.20. Siemens Healthineers AG
  • 16.21. Thermo Fisher Scientific Inc.
  • 16.22. Zhejiang Di'an Diagnostics Technology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOTYPIC ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENOTYPIC ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOTYPIC ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID AMPLIFICATION TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID AMPLIFICATION TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID AMPLIFICATION TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NONMOLECULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NONMOLECULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NONMOLECULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNOLOGICAL ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNOLOGICAL ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNOLOGICAL ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DETECTION TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DETECTION TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DETECTION TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CULTURE-BASED TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CULTURE-BASED TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CULTURE-BASED TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MOLECULAR TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MOLECULAR TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MOLECULAR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SKIN TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SKIN TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SKIN TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SMEAR MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SMEAR MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SMEAR MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MOLECULAR DST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MOLECULAR DST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MOLECULAR DST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHENOTYPIC DST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHENOTYPIC DST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHENOTYPIC DST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACTIVE TB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ACTIVE TB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACTIVE TB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EXTRAPULMONARY TB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EXTRAPULMONARY TB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EXTRAPULMONARY TB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PULMONARY TB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PULMONARY TB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PULMONARY TB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LATENT TB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LATENT TB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LATENT TB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 171. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 173. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 174. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 176. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 177. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 179. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 180. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 207. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 209. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 210. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 212. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 213. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 215. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 216. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 219. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 221. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 222. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 224. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 225. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 227. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 228. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 264. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 274. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 297. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 298. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 300. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 301. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 307. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 309. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 310. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 312. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 313. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 318. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 319. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 321. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 322. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 324. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 325. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 327. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 328. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 330. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 331. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 332. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 333. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 334. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 336. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 337. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 338. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 339. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 340. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 342. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 343. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 344. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 345. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NONMOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 346. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DETECTION TEST, 2018-2032 (USD MILLION)
  • TABLE 348. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG SUSCEPTIBILITY TESTING, 2018-2032 (USD MILLION)
  • TABLE 349. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 350. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 351. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY ACTIVE TB, 2018-2032 (USD MILLION)
  • TABLE 352. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 353. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 354. CHINA TUBERCULOSIS DIAGNO